Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBITM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.
A separate news release from Eisai on LEQEMBI pricing is also available via their website. Eisai is solely responsible for setting LEQEMBI’s price.